Clinical trial NCT03418896: Extragonadal Effects of hCG on Calcium Homeostasis
Official title: Novel Extragonadal Effects of Human Chorion Gonadotropin (hCG) on Calcium Homeostasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypogonadism
Calcium Disorder
Renal Disease
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2018-02-01
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: simple one arm intervention study
Primary purpose: BASIC_SCIENCE

Brief summary: A pilot study showed that serum calcium levels and calcium homeostasis change in response to hCG stimulation test. Serum calcium level differed when comparing pretreatment values at baseline with serum levels 72 hours after hCG stimulation in men with gonadal insufficiency referred for this stimulation test. Now we want to investigate whether this change in calcium is due to renal loss or other mechanisms and how the classical regulators of calcium homeostasis respond to hCG in men with impaired gonadal function compared with men having normal gonadal function. Moreover, the observed change in serum calcium implies that hCG also changes Phosphate, PTH and calcitonin and this will be clarified with this study

Detailed description: Aim To investigate whether human chorionic gonadotropin (hCG) stimulation test changes calcium-phosphate homeostasis in men with normal and impaired testicular function.

The overall purpose of the project is to investigate the importance of human chorion gonadotropin (hCG) for the calcium balance in normal men and men with impaired testicular function.

BACKGROUND AND HYPOTHESES

The Department for Growth and Reproduction has helped to uncover the rising occurrence of early puberty, infertility, polycystic ovarian syndrome and testicular cancer that is worryingly high in large numbers parts of the world (1). These conditions are all governed by the hormonal axis that contains hypothalamus, pituitary gland, and the HPG axis (2). Our hypothesis is, that hCG may be a new regulator of calcium balance. hCG acts like luteinizing hormone (LH) produced by the pituitary gland and stimulates by binding to the LH receptor (LHCGR) production of testosterone in the testicles (3-6). we and others have found that that LHCGR is also located in other tissues than the gonad (7) and we suggest that LH stimulation probably also regulates calcium handling in the kidney. We have observed changes in serum calcium after hCG injection in patients with impaired testicular function, which indicates that the gonads and gonadotropins may be important for calcium and phosphate homeostasis. It is compatible with the fact that it has been shown that ex FSH can regulate bone function (8),and sex hormones are important for calcium absorption and excretion in the kidney (9-11). The latter is interesting because our research suggests that the receptor for the luteinizing hormone and hCG (LHCGR) plays an important role in the kidney, thus enabling a direct effect on calcium and phosphate handling for LHCGR agonists such as LH and hCG.

With this study we want to investigate how hCG influences calcium homeostasis and subsequently other extragonadal organs by analyzing serum and urine from men with normal and impaired gonadal function

DESIGN This is a prospective intervention study in cases and controls

Patients and methods 10-15 men referred for hCG stimulation test due to suspected gonadal insufficiency after curative treatment for testicular cancer with orchiectomy, irradiation or chemotherapy age 18-80 years at Department of growth and reproduction, Rigshospitalet and 10-15 men with normal reproductive function

SAMPLE SIZE CALCULATION AND STATISTICS By using a test level of 5% (level of significance), power of 80% and at least 10 normal men and 10 men with impaired gonadal function completing the trial will enable us to detect a change in serum calcium of 6%, PTH of 25% and a change in serum Phosphate of 15%.

SCREENING AND TIME COURSE Men referred for hCG stimulation test at our Department will be screened for eligibility to the study. Those who meet the criteria for participation will be informed, and if they consent allocated to the study.

Each person will have one blood sampling performed.Venus blood is drawn before hCG administration, 2,8,24 72 and 120 hours after injection. Spot urine samples will be delivered and ECG monitoring will be performed at all time points. All men will be fasting for baseline, 2 hours, 24, 72 and 120 hours sampling. Serum will be send for analysis within 40 minutes and the rest frozen within 1 hour and will be stored at minus 80 degrees celsius until analysis.

Biostatistical analysis each individual's samples will be normalized by division of the value of the given parameter (for instance calcium or phosphate) to the baseline samples drawn before the intervention.

Hence, samples from each volunteer at the different timepoints will be normalized with the individual's own baseline values before the administration of hCG. Initially, paired Student t tests will be used to compare changes in serum or urine by comparing baseline levels with the different time points. Unpaired Student t tests will be used to compare controls and men with gonadal insufficiency at all time points. Moreover, the presumable effect of multiple testing will be tested afterwards by using ANOVA followed by a post hoc Dunnett's /SIDAK multiple comparison test. All data will after indexation to baseline levels be shown as mean ± SEM. Differences were considered statistically significant when P ≤ 0.05.

Predefined subgroups Changes in calcium and phosphate will be analyzed according to baseline sex steroids and delta sex steroids, LHCGR, BMI, GFR, PTH

Principal Investigator: Li Juel Mortensen Sponsor: Martin Blomberg Jensen

Eligibility criteria: Inclusion Criteria: to be either

* a man with normal reproductive function
* or a man with known impaired gonadal function
* more than 18 years of age and less than 80 years of age

Exclusion Criteria:

* presence of current serious diseases
* or presence of disease requiring constant and lifelong treatment with chemotherapy or other toxic drugs
* Men treated with testosterone who do not stop their treatment while being part of the study,

Primary outcomes:
measure: Serum calcium
timeFrame: 2,8,24, 72,120 hours
Secondary outcomes:
measure: urinary calcium and phosphate excretion
timeFrame: 2,8,24, 72,120 hours
measure: serum Phosphate
timeFrame: 2,8,24, 72,120 hours
Other outcomes:
measure: vitamin D metabolites
timeFrame: 2,8,24, 72,120 hours
measure: calcitonin
timeFrame: 2,8,24, 72,120 hours
measure: Cortisol
timeFrame: 2,8,24, 72,120 hours
measure: adrenal steroidogenesis
timeFrame: 2,8,24, 72,120 hours
measure: sex steroids
timeFrame: 2,8,24, 72,120 hours
measure: reproductive hormones
timeFrame: 2,8,24, 72,120 hours
measure: change in adipocyte function
timeFrame: 2,8,24, 72,120 hours
measure: LHCGR
timeFrame: 2,8,24, 72,120 hours
measure: regulators of calcium homeostasis
timeFrame: 2,8,24, 72,120 hours
measure: Kidney function
timeFrame: 2,8,24, 72,120 hours
measure: Electrocardiogram
timeFrame: 2,8,24,72,120 hours
measure: adipocyte function
timeFrame: 2,8,24,72,120 hours
measure: liver function
timeFrame: 2,8,24,72,120 hours
measure: bone function
timeFrame: 2,8,24,72,120 hours
measure: serum PTH
timeFrame: 2,8,24,72,120 hours
measure: urinary excretion of steroids
timeFrame: 2,8,24,72,120 hours
measure: Cardiovascular biomarkers
timeFrame: 2,8,24,72,120 hours
measure: glucose homeostasis
timeFrame: 2,8,24,72,120 hours
measure: incretin hormones
timeFrame: 2,8,24,72,120 hours
measure: electrolytes
timeFrame: 2,8,24,72,120 hours
Locations:
city: Copenhagen
country: Denmark
facility: Department of Growth and Reproduction, Rigshospitalet
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
affiliation: Rigshospitalet, Denmark
name: Martin blomberg Jensen
role: STUDY_CHAIR
References:
citation: Juel Mortensen L, Lorenzen M, Jorgensen A, Albrethsen J, Jorgensen N, Moller S, Andersson AM, Juul A, Blomberg Jensen M. Possible Relevance of Soluble Luteinizing Hormone Receptor during Development and Adulthood in Boys and Men. Cancers (Basel). 2021 Mar 16;13(6):1329. doi: 10.3390/cancers13061329.